Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.54 |
| ▸ | CDC42 | P60953 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.43 |
| ▸ | HTR1D | P28221 | 2/20 | 0.42 |
| ▸ | HTR1B | P28222 | 2/20 | 0.42 |
| ▸ | RB1 | P06400 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21998617 | 0.90 | PRMT5 (0.57) | PRMT5CDC42GAACASP6CYP2D6 | |
| SCHEMBL4191219 | 0.88 | SIRT1 (0.57) | PRMT5CDC42GAACASP6CYP2D6 | |
| Hydrochloric Acid SCHEMBL4161906 | 0.87 | SIRT1 (0.56) | PRMT5CDC42GAACASP6CYP2D6 | |
| SCHEMBL21996536 | 0.85 | GAA (0.67) | PRMT5CDC42GAACASP6SIRT1 | |
| SCHEMBL22135890 | 0.83 | CDC42 (0.56) | PRMT5CDC42GAACASP6CYP2D6 | |
| SCHEMBL22135891 | 0.83 | CDC42 (0.56) | PRMT5CDC42GAACASP6CYP2D6 | |
| SCHEMBL21998621 | 0.83 | CYP2D6 (0.53) | PRMT5CDC42GAACASP6CYP2D6 | |
| SCHEMBL5456604 | 0.82 | GAA (0.69) | PRMT5CDC42GAACASP6CYP2D6 | |
| SCHEMBL21996145 | 0.82 | RB1 (0.58) | PRMT5CDC42GAACASP6CYP2D6 | |
| SCHEMBL21996131 | 0.81 | RB1 (0.58) | PRMT5CDC42GAACASP6CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147069-A1 | Compounds for The Reduction of The Deleterious Activity of Extended Nucleotide Repeat Containing Genes | THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147069-A1 | Compounds for The Reduction of The Deleterious Activity of Extended Nucleotide Repeat Containing Genes | NSUN2, RNMT, RRM2B | PRMT5 691/4885CDC42 1897/4885GAA 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.